ML
Mark Levis
Physician · Johns Hopkins School of Medicine
Credentials: · · ·
History
- 1997–1999
Medical Oncology
- 1994–1997
Internal Medicine
Research
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Review · Leukemia · 2019 · Last of 4 authors · Corresponding · 869 citations
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Nature · 2012 · 623 citations
- BS
56 papers
- DS
46 papers
42 papers
- AD
41 papers · 1 as a fellow
- IG
39 papers
34 papers
- GG
32 papers
- LG
28 papers
